Research letter: BRAF-inhibitor induced panniculitis- A systematic review Supplemental Material

To identify the common clinicopathological characteristics and management of BRAF-inhibitor induced panniculitis (BiP) we performed a systematic review that summarizes the current literature reporting the development of BiP. BiP appears to be a mild cutaneous adverse reaction that may benefit from symptomatic management without targeted therapy cessation. The following supplemental materials include a figure representing the schematic overview of our systematic review and tables of search terms and data points collected from the included reports. Additional tables of summarized patient characteristics and histopathology results, individual patient demographics and clinical findings, and the references of the studies included in this review.